(ANEB) Anebulo Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0345691036
ANEB: Cannabis, Antidote, Treatment, Medicine, Antagonist, Receptor
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) is a clinical-stage biotechnology company focused on developing treatments for cannabinoid-related medical conditions, including unintentional cannabis poisoning, acute cannabinoid intoxication, and cannabis-induced acute conditions. The companys lead product candidate, selonabant, is a small molecule antagonist targeting the cannabinoid binding receptor type-1 (CB1), currently in Phase II clinical trials. This candidate aims to address the growing need for a specific antidote to cannabis toxicity, leveraging its mechanism to counteract CB1 receptor overactivation. Incorporated in 2020 and headquartered in Lakeway, Texas, Anebulo operates in a niche therapeutic area with limited competition, positioning itself to potentially capture a significant share of the emerging market for cannabinoid toxicity treatments.
Based on the provided data, the 3-month forecast for Anebulo Pharmaceuticals suggests cautious optimism. Technically, the stock is trading below its 20-day, 50-day, and 200-day moving averages (SMA 20: $1.30, SMA 50: $1.46, SMA 200: $1.84), indicating bearish momentum. The average trading volume of 8,515 shares over 20 days reflects low liquidity, which could lead to volatility. The ATR of $0.13 suggests moderate price fluctuations. Fundamentally, the companys market cap of $42.79M and negative return on equity (-51.24%) highlight its early-stage nature and ongoing R&D investments. However, the high price-to-book ratio (P/B: 3.19) signals investor confidence in its pipeline. If Phase II trials for selonabant demonstrate efficacy, the stock could experience upward pressure, potentially breaking above the SMA 50 and 200 levels. Conversely, failure or delays in trials may deepen the downtrend. The next 3 months will likely hinge on clinical trial progress and broader market sentiment toward speculative biotech stocks.
Additional Sources for ANEB Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ANEB Stock Overview
Market Cap in USD | 43m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2021-05-07 |
ANEB Stock Ratings
Growth 5y | -80.6% |
Fundamental | -44.5% |
Dividend | 0.0% |
Rel. Strength Industry | -23.5 |
Analysts | 5/5 |
Fair Price Momentum | 1.14 USD |
Fair Price DCF | - |
ANEB Dividends
No Dividends PaidANEB Growth Ratios
Growth Correlation 3m | -35% |
Growth Correlation 12m | -91.6% |
Growth Correlation 5y | -89.8% |
CAGR 5y | -30.87% |
CAGR/Max DD 5y | -0.35 |
Sharpe Ratio 12m | -0.04 |
Alpha | -37.63 |
Beta | 0.63 |
Volatility | 167.74% |
Current Volume | 46.2k |
Average Volume 20d | 11k |
As of March 16, 2025, the stock is trading at USD 1.71 with a total of 46,214 shares traded.
Over the past week, the price has changed by +59.81%, over one month by +28.57%, over three months by +31.54% and over the past year by -29.34%.
Probably not. Based on ValueRay Fundamental Analyses, Anebulo Pharmaceuticals (NASDAQ:ANEB) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.45 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ANEB as of March 2025 is 1.14. This means that ANEB is currently overvalued and has a potential downside of -33.33%.
Anebulo Pharmaceuticals has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy ANEB.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ANEB Anebulo Pharmaceuticals will be worth about 1.3 in March 2026. The stock is currently trading at 1.71. This means that the stock has a potential downside of -24.56%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 6 | 250.9% |
Analysts Target Price | 6 | 250.9% |
ValueRay Target Price | 1.3 | -24.6% |